Principles for Artificial Intelligence in Medical and Digital Health Technologies

Hear from AdvaMed’s data privacy expert, Terry Chang, on the critical exemptions we seek in comprehensive data privacy laws across the country.

AdvaMed’s digital health policy expert, Geeta Pamidimukkala, and payment and health care delivery policy expert, Kirsten Tullia, break down how artificial intelligence and machine learning (AI/ML) technologies are transforming patient care and the FDA’s crucial role in overseeing AI-powered medical devices.

Jones Lang Lasalle Inc. is the trusted real estate advisor to over 100 AdvaMed members across the globe and will be presenting the tools and strategies they have employed to achieve facility savings and mitigate risk within this very dynamic real estate market.

AdvaMed, the Medtech Association, commended the House of Representatives’ bipartisan Task Force on Artificial Intelligence for urging the Centers for Medicare & Medicaid Services (CMS) to develop a formalized payment pathway for AI-enabled medical devices. AI-enabled medical devices are FDA-cleared and produce clinical information to aid in patient diagnosis or treatment.

Join Porzio in this session that will help med device compliance leaders with messaging, designing, and implementing risk assessments, a key component of an effective healthcare compliance program.

This white paper explores the evolution of current biopharmaceutical commercial models. By addressing key considerations essential for every healthcare leader, this shares the impact of integrating
digital assets clinician engagement
and enhancing health outcomes.

The industry is at the forefront of physical and digital technologies, with implications for research, development, manufacturing and patient care. Digital technologies and workflows can unlock discoveries, leading
to new markets, opportunities and better outcomes.

Join King & Spalding for this engaging panel that will cover common experiences and practical considerations for advising medical device company executives during a government investigation.